Skip to main content
TipRanks
Go Ultimate75% OFF

Kiora Pharmaceuticals (KPRX) AI Stock Analysis

487 Followers
KPRX

Kiora Pharmaceuticals

(NASDAQ:KPRX)

Select Model
Rating:46Neutral
Price Target:$0.96â–¼(-2.04% Downside)
Action:reiterated
Date:11/17/26

The score is held down primarily by weak financial performance (ongoing losses, unstable revenue, and negative free cash flow) and bearish technical momentum (price far below key moving averages with negative MACD). Positive pipeline/licensing and leadership events provide some support, but valuation is not a clear positive due to negative earnings and no dividend yield data.

Positive Factors
Late-stage ophthalmology pipelineKIO-401 gives Kiora a late-stage ophthalmology asset with prior clinical data in CRAO, a condition described as having no approved therapies. The planned multinational Phase 3 could broaden the company’s development platform and create a more substantial foundation for future product commercialization.
Negative Factors
Persistent losses and weak profitabilityDeep losses relative to the current revenue base show that Kiora has not yet established profitable operating economics. Continued negative margins reduce internally generated funding for clinical programs and make future progress dependent on improving revenue, licensing proceeds or additional financing.

Kiora Pharmaceuticals (KPRX) vs. SPDR S&P 500 ETF (SPY)

-60%-40%-20%0%20%40%60%KPRX-45.44%SPY+12.87%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$4.34M
Dividend Yield
―
Average Volume (3M)
32.08K
Price to Earnings (P/E)
-0.3
Beta (1Y)
1.17
Revenue Growth
―
EPS Growth
-18.90%
Country
US
Employees
13
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Kiora Pharmaceuticals Business Overview & Revenue Model

Company Description

Kiora Pharmaceuticals, Inc., a specialty pharmaceutical firm operating at the clinical stage, is dedicated to the creation and commercialization of treatments for various ophthalmic conditions across the United States. Its flagship therapeutic candid...

How the Company Makes Money

As a clinical-stage biotech, Kiora Pharmaceuticals does not have an established, recurring product-sales business in the way commercial-stage pharmaceutical companies do. Publicly available information about Kiora’s specific, ongoing revenue-generati...

Kiora Pharmaceuticals Financial Statement Overview

Summary

Overall fundamentals are weak due to persistent losses and cash burn: TTM revenue is ~$1.0M with a net loss of ~$12.8M and negative margins, and operating/free cash flow are negative (FCF about -$7.8M to -$7.9M). The balance sheet is a partial offset with very low leverage (debt-to-equity ~0.02), but returns are sharply negative (ROE about -82%) and results have been volatile (profitable 2024 followed by zero-revenue losses in 2025).

Income Statement

18Very Negative

Balance Sheet

68Positive

Cash Flow

22Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue1.00M016.00M000
Gross Profit903.94K-24.80K16.00M000
EBITDA-11.27M-12.07M5.70M-12.36M-13.65M-13.91M
Net Income-12.76M-10.84M3.59M-12.51M-13.58M-13.77M
Balance Sheet
Total Assets22.37M24.25M36.48M13.71M18.68M20.13M
Cash, Cash Equivalents and Short-Term Investments16.29M17.09M26.79M2.45M5.96M7.85M
Total Debt286.79K368.26K57.17K106.89K105.78K209.41K
Total Liabilities7.08M8.13M10.72M7.60M7.27M5.55M
Stockholders Equity15.30M16.13M25.76M6.11M11.41M14.58M
Cash Flow
Free Cash Flow-7.90M-10.07M8.55M-9.56M-10.43M-10.74M
Operating Cash Flow-7.79M-9.96M8.56M-9.56M-10.43M-10.68M
Investing Cash Flow2.90M14.43M-22.66M06,375-157.02K
Financing Cash Flow4.91M265.65K15.50M5.97M8.62M17.58M

Kiora Pharmaceuticals Technical Analysis

Technical Analysis SentimentNegative
Last Price0.98

Price Trends

50DMA2.25Negative
100DMA2.41Negative
200DMA2.37Negative

Market Momentum

MACD-0.33Positive
RSI16.98Positive
STOCH2.77Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KPRX, the sentiment is Negative. The current price of 0.98 is below the 20-day moving average (MA) of 1.76, below the 50-day MA of 2.25, and below the 200-day MA of 2.37, indicating a bearish trend. The MACD of -0.33 indicates Positive momentum. The RSI at 16.98 is Positive, neither overbought nor oversold. The STOCH value of 2.77 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KPRX.

Kiora Pharmaceuticals Risk Analysis

Kiora Pharmaceuticals disclosed 50 risk factors in its most recent earnings report. Kiora Pharmaceuticals reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Kiora Pharmaceuticals Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

KPRX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
KPRXKPRX46Neutral$4.34M-0.34-82.06%――-18.90%
GTBPGTBP43Neutral$7.29M-0.03-443.08%――75.09%
BCDABCDA41Neutral$11.96M-1.26-912.37%――62.51%
INABINAB41Neutral$8.82M-0.70-93.66%――81.16%
KALAKALA41Neutral$2.47M-0.00-222.32%――78.25%
BRTXBRTX38Underperform$1.96M-0.06-423.84%―-8.47%25.62%

* Healthcare Sector Average

Performance Comparison

-100%-50%0%50%100%KPRXGTBPKALABRTXBCDAINABDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
KPRX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
KPRXKiora Pharmaceuticals, Inc.0.98-0.94-48.85%
GTBPGt Biopharma, Inc.3.54-13.46-79.21%
KALAKala Bio, Inc.3.83-945.67-99.60%
BRTXBiorestorative Therapies, Inc.1.42-27.18-95.03%
BCDABiocardia0.79-0.53-40.15%
INABIn8bio, Inc.0.82-0.80-49.63%

Kiora Pharmaceuticals Corporate Events

Business Operations and StrategyPrivate Placements and FinancingProduct-Related Announcements

Kiora Pharmaceuticals Licenses KIO-401, Refocuses Pipeline Strategy

Positive
Oct 29, 2026

On October 23, 2026, Kiora Pharmaceuticals entered into an exclusive license agreement with Japan-based Senju Pharmaceutical to in-license KIO-401, an oral neuroprotective calpain inhibitor, securing development and commercialization rights outside A...

Business Operations and StrategyExecutive/Board Changes

Kiora Pharmaceuticals Bolsters Leadership in Clinical Development

Positive
Sep 8, 2026

On September 8, 2026, Kiora Pharmaceuticals appointed Keith J. Lane as Executive Vice President of Clinical Development and Regulatory Affairs, strengthening its leadership in ophthalmic drug development. Lane brings more than 20 years of experience...

Business Operations and StrategyPrivate Placements and Financing

Kiora Licenses KIO-301 Rights in South Korea

Positive
Aug 19, 2026

On August 20, 2026, Kiora Pharmaceuticals entered an exclusive license and development agreement with Chong Kun Dang Pharmaceutical Corporation granting CKD rights to develop, manufacture and commercialize its KIO-301 molecular photoswitch in South K...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 17, 2026